A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects With Type 1 Diabetes Mellitus - Study Two
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 26 Oct 2017
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms DEPICT 2
- Sponsors AstraZeneca
- 10 Jun 2017 Biomarkers information updated
- 12 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 08 Dec 2016 Planned End Date changed from 1 Jan 2018 to 1 Apr 2018.